Exponent, Inc. research snapshot
EXPO AI stock analysis reads Exponent as a high-margin engineering and scientific consulting business with accelerating growth, a clean balance sheet, strong free cash flow, and a reputation that supports premium billing rates. As of the August 4, 2026 cutoff, the latest verified close was $68.27 on August 3, 2026, implying a market capitalization near $3.31 billion. Q2 2026 delivered double-digit revenue and earnings growth, utilization reached 74%, and management raised full-year guidance, with demand for AI-enabled product user research and failure analysis cited as a key driver. The main tension is valuation: the stock still trades near 30x trailing earnings, so the analysis favors scenario-based research over a certain price prediction, with the risk centered on utilization, litigation-cycle dependence, and multiple compression if growth slows.
Current price
$68.27
Market cap
$3.31 billion
AI score
72 / 100
Rating
High-margin consulting franchise with accelerating AI-linked demand
Trend status
Uptrend forming, price above the 50-day and 200-day moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Exponent provides engineering and scientific consulting to law firms, insurers, corporations, and government clients. It operates across more than 90 technical disciplines with about 950 consultants, billing hourly and on fixed-fee engagements. | High |
| Moat | The moat is built on brand reputation, decades of expert witness credibility, a deep bench of PhD-level scientists and engineers, and recurring relationships with top defense litigation firms. It is durable but narrow, since talent can be hired away. | Medium-high |
| Management | Management has run a capital-efficient business with a debt-free balance sheet apart from operating leases, 12 consecutive years of dividend growth, and aggressive buybacks that returned $272 million over the trailing twelve months. Insider ownership is modest at about 1.2%. | Medium-high |
| Financial trend | Q2 2026 revenue before reimbursements rose 12% and total revenue rose 21%, with diluted EPS up from $0.52 to $0.60. TTM operating margin is about 22.5%, ROE is about 31%, and free cash flow conversion is strong. | High |
| Valuation | At about 30.6x trailing EPS, 27.6x forward EPS, 11.5x book value, and 29.2x TTM free cash flow, EXPO trades at a premium that assumes continued double-digit growth. A multiple contraction would meaningfully reduce returns. | Medium |
| Technical trend | Price at $68.27 sits above both the 50-day SMA near $60.15 and the 200-day SMA near $67.06, with RSI near 68 showing strengthening momentum after a rally from June lows around $55. Volume expanded on the July 30 earnings release. | Medium |
| Risk level | Key risks are utilization sensitivity, litigation-cycle dependence, key-person concentration among senior engineers, a modest revenue visibility profile, and a premium valuation that leaves little room for execution misses. | Medium-high |
| AI confidence | High for descriptive analysis, financial math, and analyst consensus. Lower for forward returns because utilization, billing rates, and litigation timing are inherently variable and the entry multiple leaves a limited buffer. | High data confidence |
| Investment certainty | Exponent is a well-run, growing business with durable margins and a strong balance sheet, but the entry price at about 30.6x earnings reduces the margin of safety. A wider margin would require either a lower price or continued double-digit growth. | Medium |
EXPO AI stock forecast
The EXPO AI stock forecast should be read as scenario math, not a promise. Using the August 3, 2026 close near $68.27, TTM EPS near $2.23, and a three-year framework, the tested range spans a bearish area near $57, a base area near $80, and a bullish area near $106. These outputs depend on EPS growth, utilization rates, billing rate increases, and the terminal earnings multiple.
$95 to $115
More likely if demand for AI-enabled product user research and failure analysis keeps accelerating, utilization stays at or above 74%, billing rates rise faster than compensation costs, and investors sustain a low-30s earnings multiple.
$75 to $88
More likely if Exponent grows EPS in the high-single to low-double-digit range, EBITDA margins stay near 28% of revenue before reimbursements, and the stock trades near the consensus price target of $84.
$50 to $62
More likely if utilization drops below 65%, litigation or discretionary user research demand softens, competition pressures billing rates, or the market re-rates the stock toward the low 20s earnings multiple.
EXPO AI technical analysis
EXPO AI technical analysis shows a strengthening uptrend. As of the August 2026 data used for this page, price at $68.27 held above both the 50-day SMA near $60.15 and the 200-day SMA near $67.06 after a rally from June lows around $55. RSI near 68 points to positive momentum but is approaching overbought, and the 52-week range spans $51.91 to $81.95.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $68.27 | Close on August 3, 2026, up 2.12% on the day. |
| Near support | $64.50 to $66.00 | July consolidation lows and a short-term demand zone. |
| Deeper support | $60.00 to $62.50 | Area around the 50-day SMA near $60.15 and late-June swing lows. |
| Major support | $55.00 to $57.50 | June swing low area that preceded the current rally. |
| Near resistance | $69.50 to $70.50 | August 3 intraday high near $69.54 and round-number supply. |
| Upper resistance | $76.00 to $78.00 | Mid-range supply zone from the post-earnings move. |
| 52-week high | $81.95 | Upper boundary of the 52-week trading range. |
| 50-day SMA | $60.15 | Moving average support well below current price. |
| 200-day SMA | $67.06 | Long-term trend line that price recently reclaimed. |
| Momentum | RSI near 68 | Positive momentum, approaching but not yet overbought. |
| Volatility | Low beta near 0.68 | Lower volatility than the broad market; position sizing can still account for post-earnings gaps. |
| Invalidation | Close below $64.50 | A decisive close below the near-support zone would signal a short-term shift and challenge the recent uptrend. |
EXPO AI trading strategy
The EXPO AI trading strategy below is a research and risk-control framework, not personalized advice. It combines business evidence, technical confirmation, and predefined invalidation levels.
Let EXPO hold above the 200-day SMA near $67.06 and confirm a break above $69.50 to $70.50 on above-average volume, with RSI momentum staying constructive and utilization reports staying at or above 70%.
A failed move back below $67 or a close below $64.50 should invalidate the setup.
If EXPO pulls back toward $64.50 to $66.00 without material business deterioration, treat that zone as a reference for a potential bounce, confirmed by RSI resetting from overbought levels.
Avoid averaging down. Define maximum loss and position size before entry. A close below $64.50 invalidates the reversion thesis.
Track quarterly revenue per consultant, utilization rates, billing rate trends, headcount growth, operating margin trajectory, the split between proactive and reactive work, and demand from AI-enabled product clients.
Reduce confidence when utilization falls below 65%, margins compress, key technical talent departs, or management walks back the raised full-year guidance.
Investment research summary
Exponent sells independent, court-admissible engineering and scientific analysis to clients who face high-consequence technical questions in litigation, regulation, and product safety. Customers pay for the firms reputation, the depth of its multidisciplinary talent, and the credibility of its work product when failure costs are extreme.
The moat is built from decades of brand trust, a deep bench of PhD-level scientists and engineers across 90+ disciplines, long-standing relationships with top law firms and corporations, and the high cost of replacing a trusted expert mid-litigation. It is durable but narrow, since competitors can hire talent and clients can choose other reputable firms.
The thesis fails if utilization drops as discretionary work slows, if litigation volume declines or tort reform reduces dispute work, if clients bring technical work in-house, if key senior engineers retire or defect, if billing rate growth lags compensation inflation, or if a high-profile failure damages the brand.
Exponent management has demonstrated disciplined capital allocation, 12 consecutive years of dividend growth, aggressive buybacks that returned $272 million in the trailing twelve months, and steady investment in technical talent. CEO Dr. Catherine Corrigan and CFO Eric Anderson have consistently guided to premium EBITDA margins near 28%.
Exponent operates at the intersection of litigation, regulation, and engineering complexity. As AI-enabled products spread into physical devices, demand for user research, human factors work, and failure analysis is growing. The long-term trend is supportive, but litigation volume remains cyclical and can shift with tort reform or insurance-market changes.
At roughly $68.27 and $3.31 billion market cap, EXPO trades near 30.6x trailing earnings and 29.2x free cash flow, a premium that assumes continued double-digit growth. Margin of safety is modest; the stock would offer a better risk-reward at a lower entry multiple closer to 25x earnings.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| EXPO price | $68.27 close on August 3, 2026 | Available market data | August 4, 2026 |
| Market capitalization | $3.31 billion, verified as $68.27 x 48.51 million shares (0.05% deviation) | financial_rigor.py market-cap verification | August 4, 2026 |
| Shares outstanding | 48.51 million, down 2.69% year over year | Available market data | August 4, 2026 |
| Q2 2026 results | Revenue before reimbursements up 12% to $148.9 million; total revenue up 21% to $171.6 million; diluted EPS $0.60; EBITDA 28.7% of revenue before reimbursements; utilization 74% | Exponent Q2 2026 earnings release, July 30, 2026 | August 4, 2026 |
| TTM revenue | $567.13 million before reimbursements, up about 9% | Available financial data | August 4, 2026 |
| TTM EPS | ~$2.23 per share | Available financial data | August 4, 2026 |
| Book value per share | ~$5.92 | Available financial data | August 4, 2026 |
| TTM free cash flow per share | ~$2.34 per share; TTM FCF $113.39 million | Available financial data | August 4, 2026 |
| Annual dividend | $1.24 per share, 1.82% yield, 12 years of dividend growth | Available dividend data | August 4, 2026 |
| Balance sheet | Cash and equivalents $66.63 million. Total debt $80.72 million, essentially operating lease obligations. Net cash negative $14.09 million after heavy buybacks. | Q2 2026 balance sheet and available data | August 4, 2026 |
| Capital returns | $272 million returned to shareholders over the trailing twelve months; $146.1 million of buybacks in H1 2026; buyback authorization increased by $50 million; quarterly dividend raised to $0.31 | Exponent Q2 2026 earnings release | August 4, 2026 |
| Valuation ratios | PE 30.6x, forward PE 27.6x, PB 11.5x, P/FCF 29.2x, ROE 31.2%, FCF yield 3.4% | financial_rigor.py valuation verification | August 4, 2026 |
| Analyst consensus | Buy consensus from 4 analysts, average price target $84.00, range $72 to $90 | Available analyst data | August 4, 2026 |
| Scenario valuation | Three-year framework: bear near $57, base near $80, bull near $106 | financial_rigor.py three-scenario calculation | August 4, 2026 |
This EXPO AI stock analysis page is an informational research tool only and is not investment advice, a recommendation, or a personalized trading plan. Forecast scenarios are based on available public data as of the stated cutoff date, may be wrong, and should be checked against current filings, market data, and your own risk constraints.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
